AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Read Moreby Jen Brogan | May 30, 2023 | News | 0
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Read Moreby Lucy Parsons | Jul 26, 2021 | News | 0
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
Read Moreby Lucy Parsons | May 11, 2021 | News | 0
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read Moreby Lucy Parsons | Apr 16, 2021 | News | 0
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Read Moreby Lucy Parsons | Feb 9, 2021 | News | 0
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read Moreby Selina McKee | Jul 4, 2019 | News | 0
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read Moreby Anna Smith | Jan 29, 2019 | News | 0
Alexion Pharmaceuticals’ Ultomiris has been found to be successful in treating atypical haemolytic uremic syndrome (aHUS) in a Phase III study.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
